Accelerate Diagnostics (NASDAQ:AXDX) Stock Price Passes Below Two Hundred Day Moving Average – What’s Next?

Accelerate Diagnostics, Inc. (NASDAQ:AXDXGet Free Report) shares passed below its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $1.54 and traded as low as $1.20. Accelerate Diagnostics shares last traded at $1.39, with a volume of 137,612 shares.

Analysts Set New Price Targets

Several research analysts have recently weighed in on AXDX shares. BTIG Research upgraded Accelerate Diagnostics to a “strong-buy” rating in a report on Wednesday, December 11th. StockNews.com assumed coverage on Accelerate Diagnostics in a research note on Tuesday. They set a “hold” rating on the stock.

Check Out Our Latest Stock Report on Accelerate Diagnostics

Accelerate Diagnostics Price Performance

The company has a market capitalization of $34.81 million, a PE ratio of -0.49 and a beta of 0.59. The business’s 50 day simple moving average is $1.32 and its 200 day simple moving average is $1.54.

Insider Transactions at Accelerate Diagnostics

In other Accelerate Diagnostics news, Director John Patience acquired 200,000 shares of the stock in a transaction that occurred on Tuesday, December 3rd. The stock was bought at an average cost of $1.57 per share, for a total transaction of $314,000.00. Following the completion of the transaction, the director now owns 653,224 shares of the company’s stock, valued at approximately $1,025,561.68. The trade was a 44.13 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Insiders own 43.60% of the company’s stock.

Institutional Investors Weigh In On Accelerate Diagnostics

A hedge fund recently bought a new stake in Accelerate Diagnostics stock. Y Intercept Hong Kong Ltd acquired a new stake in Accelerate Diagnostics, Inc. (NASDAQ:AXDXFree Report) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 19,866 shares of the medical research company’s stock, valued at approximately $34,000. Y Intercept Hong Kong Ltd owned approximately 0.08% of Accelerate Diagnostics at the end of the most recent quarter. 17.14% of the stock is owned by hedge funds and other institutional investors.

Accelerate Diagnostics Company Profile

(Get Free Report)

Accelerate Diagnostics, Inc, an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms.

Further Reading

Receive News & Ratings for Accelerate Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accelerate Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.